Figure 3.
(A) Covalent reactivity of A.17 and A.5 and their mutants. Concentrations of scFvs were normalized as confirmed by comparable staining in anti-c-Myc blot (lower panel). (B) Binding efficiency of clones selected after the third round, including reactive clones A.5, A.17 and their non-reactive mutants A.5Y32F and A.17Y36F. Non-selected clone (N) and anti-thyroglobulin scFv (anti-Thyr) were included as negative controls. Binding was determined as described in Methods.